OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
NCT ID: NCT04389437
Last Updated: 2025-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
450 participants
INTERVENTIONAL
2020-06-26
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
These retinal anomalies objectified by OCT-A (Optical coherence tomography angiography) and adaptive optics (AO) appear different depending on the pathologies and could therefore serve as markers in vivo of the pathophysiological processes underlying NCD.
No study to date has studied the retina and its vessels in NCD using adaptive optics. In this pilot study, we are proposing a combination of two new ophthalmological imaging techniques (OCT-A and AO), which allow rapid in vivo analysis in a completely non-invasive way of the morphology of small vessels as well as architecture of the retina to better specify the retinal anomalies associated with NCD. We will compare the parameters in OCT-A and AO between patients with NCD and controls without NCD (with memory complaint or without) and will seek to determine if there are different profiles according to the causes of NCD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relationship Between Alzheimer Disease and Diminution of the Three Macular Nervous Retinal Layers
NCT04794634
Optical Coherence Tomography in Cerebral Amyloidosis
NCT03472482
OCT Angiography and NRAI in Dementia
NCT03761381
Retinal Neurodegenerative Signs in Alzheimer's Diseases
NCT01555827
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
NCT06023446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NCD patients (case)
Patient diagnosed with Alzheimer's disease or parkinsonian dementia / Lewy body dementia or other mild or severe NCD defined by international criteria.
Ophthalmological exam
OCT-A and AO
Blood pressure measurement
Blood pressure measurement before the ophthalmological exam
Control patients with memory complaint
Normal neuropsychological evaluation during assessment
Ophthalmological exam
OCT-A and AO
Blood pressure measurement
Blood pressure measurement before the ophthalmological exam
Control patients without memory complaint
MMS score and / or the Montreal Cognitive Assessment grid (MoCA) ≥26 / 30, No memory complaint
Ophthalmological exam
OCT-A and AO
Blood pressure measurement
Blood pressure measurement before the ophthalmological exam
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ophthalmological exam
OCT-A and AO
Blood pressure measurement
Blood pressure measurement before the ophthalmological exam
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* history of known non-degenerative neurological pathology (tumor, stroke territorial, in particular multiple sclerosis)
* history of retinal pathology
* ametropia greater in absolute value than 3 diopters on the sphere, or/and 1.5 diopters on the cylinder.
* history of taking ethambutol for more than 2 months
* history of takingsynthetic antimalarial for more than 2 years
* Mini Mental State Score (MMS) and / or Montreal Cognitive Assessment (MoCA) \<10 for patients and 26 for accompanying persons
* MRI contraindication (for patients only)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antoine MOULIGNIER, MD
Role: PRINCIPAL_INVESTIGATOR
Fondation A. de Rothschild
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Fondation A. de Rothschild
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMR_2020_3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.